X

Drug Profile

Caffeine citrate - Mead Johnson

Alternative Names: Cafcit

Latest Information Update: 25 Sep 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mead Johnson
Class Respiratory stimulants; Small molecules; Xanthines
Mechanism of Action Phosphoric diester hydrolase inhibitors; Purinergic P1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Apnoea
New Molecular Entity No

Highest Development Phases

Marketed Apnoea

Most Recent Events

03 Jan 2008 Caffeine citrate licensed to Bedford Laboratories
15 May 2003 Mead Johnson, a Bristol-Myers Squibb subsidiary, has purchased Cafcit^® from OPR Development
31 Dec 2000 Launched for Apnoea in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com